Why should we still care about the stavudine dose?

Southern African Journal of HIV Medicine

Volumn , Issue 42, 2011, Pages 14-15

  Innes, Steve ^a   Cotton, Mark ^a   Venter, François ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS STAVUDINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY FUNCTION; LIPOATROPHY; NOTE; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84856143244     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v12i4.166     Document Type: Note

References (20)

1. UNAIDS. Report on the Global AIDS Epidemic. 2010. http://wwwunaidsorg/ globalreport/global-report.htm (accessed 8 September 2011).
2. Renaud-Thery F, Avila-Figueroa C, Stover J, et al. Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS Research and Treatment 2011;2011. doi:10.1155/2011/749041. http://www.hindawi.com/journals/art/2011/749041/cta/ (accessed 15 November 2011).
3. World Health Organization. Forecasting antiretroviral demand. 2010. http://www.who.int/hiv/amds/forecasting/en/index4.html (accessed 15 September 2011).
4. Anderson RE, Dunkle LM, Smaldone L, et al. Design and implementation of the stavudine parallel-track program. J Infect Dis 1995;171(suppl 2):S118-122.
5. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995;171(suppl 2):S131-139.
6. Pollard RB, Peterson D, Hardy D, et al. Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. J Acquir Immune Defic Syndr 1999;22(1):39-48. (Pubitemid 29486908)
7. Ruxrungtham K, Kroon ED, Ungsedhapand C, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 2000;14(10):1375-1382. (Pubitemid 30459510)
8. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med 1997;126(5):355-363. (Pubitemid 27102519)
9. Kaul S, Kline MW, Church JA, Dunkle LM. Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2001;45(3):758-763. (Pubitemid 32182021)
10. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995;96:247-252.
11. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-58. (Pubitemid 28190689)
12. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16(18):2447-2454. (Pubitemid 35471693)
13. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007;8(5):679-688. (Pubitemid 46547020)
14. World Health Organization. Addendum to 2006 WHO Guidelines on Antiretroviral Therapy for HIV Infection in Adults and Adolescents. 2007. http://wwwwho.int/hiv/art/ARTadultsaddendum.pdf (accessed 26 August 2008).
15. McComsey GA, Lo Re V, 3rd, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008;46(8):1290-1296. (Pubitemid 351589916)
16. Milinkovic A, Martinez E, Lopez S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007;12(3):407-415. (Pubitemid 46787986)
17. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity HIV Clin Trials 2005;6(4):197-202. (Pubitemid 41601131)
18. Southern African HIV Clinicians Society. Antiretroviral pricelist. 2010. http://www.sahivsocorg/indexARVphp/arvpricelist (accessed 1 September 2011).
19. Wood R. The role of stavudine in the South African public sector antiretroviral programme: Should the perfect be the enemy of the good? Southern African Journal of HIV Medicine 2006;7(2):5-8.
20. Walensky RP, Wood R, Ciaranello AL, et al. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med 2010;7(12):e1000382.